Anchor Sinks $10M Series B, Aileron Lands Deal with Roche, C Change Launches Fund With Vanterra, & More Boston-Area Deals News
(Page 2 of 2)
the company’s funding pot to $23.5 million.
—After a busy month of deal-making in June, Massachusetts startups brought in a much smaller total of $131 million in July, according to data from CB Insights. The month’s biggest deal was a $24 million Series A round for Euthymics Bioscience.
—Cambridge-based Taligen Therapeutics received a $10 million investment to put toward developing its drug for targeting autoimmune disease. The financing comes from Alta Partners, Clarus Ventures, High Country Venture, and Sanderling Ventures.
—Cambridge biotech Aileron Therapeutics inked a deal with Swiss drug and diagnostics company Roche that could be worth up to $1.1 billion. Under the agreement, Roche will provide at least $25 million in technology access fees and R&D support to Aileron, to develop and commercialize a new class of drugs called “stapled peptides.”
—Cambridge-headquartered fund manager C Change Investments partnered on a new fund with Vanterra Capital, raising $100 million in an initial close earlier in August. The Vanterra C Change Transformative Energy & Materials Fund I will invest in companies whose technologies help make industrial operations more energy efficient.
—New medical imaging startup Photo Diagnostic Systems, of Danvers, MA, nailed down $5 million in equity-based funding. Analogic and NeuroLogica founder Bernard Gordon, who bought the assets of the now defunct Photo Detection Systems, started the new company by investing through the Gordon Charitable Remainder Trust.